

Bianca Weinstock-Guttman

List of Publications by Citations

Source: <https://exaly.com/author-pdf/828888/bianca-weinstock-guttman-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

472
papers

21,661
citations

74
h-index

129
g-index

485
ext. papers

24,648
ext. citations

5.1
avg, IF

6.52
L-index

#	Paper	IF	Citations
472	Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). <i>Annals of Neurology</i> , 1996 , 39, 285-94	9.4	2075
471	Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2006 , 354, 911-23	59.2	1048
470	Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). <i>Journal of the International Neuropsychological Society</i> , 2006 , 12, 549-58	3.1	494
469	Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. <i>Journal of the Neurological Sciences</i> , 2005 , 231, 29-34	3.2	378
468	Thalamic atrophy and cognition in multiple sclerosis. <i>Neurology</i> , 2007 , 69, 1213-23	6.5	363
467	Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. <i>Annals of Neurology</i> , 1998 , 43, 79-87	9.4	310
466	Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. <i>Archives of Neurology</i> , 2004 , 61, 226-30		304
465	The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. <i>Neurology</i> , 2007 , 69, 1391-403	6.5	263
464	Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). <i>Neurology</i> , 1998 , 50, 1266-72	6.5	256
463	Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. <i>Archives of Neurology</i> , 2006 , 63, 1301-6		253
462	Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. <i>Lancet Neurology</i> , 2007 , 6, 773-81	24.1	249
461	Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 393-6	5	244
460	Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 52-7	5	238
459	Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. <i>Neurology</i> , 2006 , 66, 685-92	6.5	233
458	Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. <i>Journal of Neurology</i> , 2012 , 259, 139-46	5.5	227
457	Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. <i>Neurology</i> , 2004 , 63, 2039-45	6.5	214
456	Reliable screening for neuropsychological impairment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 675-8	5	194

455	Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 228-37	5	189
454	The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. <i>Annals of Neurology</i> , 1995 , 37, 7-15	9.4	178
453	Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. <i>Neurology</i> , 2011 , 77, 138-44	6.5	166
452	The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. <i>Journal of Neurology</i> , 2009 , 256, 405-15	5.5	164
451	Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. <i>NeuroImage</i> , 2012 , 59, 331-9	7.9	160
450	Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. <i>Clinical Neuropsychologist</i> , 2010 , 24, 1131-45	4.4	160
449	Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 1077-84	5	155
448	Management of multiple sclerosis. <i>New England Journal of Medicine</i> , 1997 , 337, 1604-11	59.2	152
447	Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 940-6	5	146
446	Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). <i>Archives of Neurology</i> , 2006 , 63, 957-63		144
445	Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2011 , 8, 127	10.1	143
444	The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. <i>NeuroImage</i> , 2005 , 26, 1068-77	7.9	142
443	MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. <i>Neurology</i> , 2014 , 82, 1491-8	6.5	141
442	Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009 , 80, 201-6	5.5	139
441	Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2005 , 73, 397-404	2.8	137
440	Health-related quality of life in multiple sclerosis: effects of natalizumab. <i>Annals of Neurology</i> , 2007 , 62, 335-46	9.4	136
439	The utility of regression-based norms in interpreting the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). <i>Journal of the International Neuropsychological Society</i> , 2010 , 16, 6-16	3.1	133
438	Diversity and plasticity of self recognition during the development of multiple sclerosis. <i>Journal of Clinical Investigation</i> , 1997 , 99, 1682-90	15.9	133

437	Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 437-44	5	131
436	Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2018 , 379, 846-855	59.2	131
435	Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2008 , 268, 12-7	3.2	129
434	Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. <i>Neurology</i> , 2014 , 82, 1083-92	6.5	125
433	Unemployment in multiple sclerosis: the contribution of personality and disease. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 647-53	5	123
432	Gut microbiota composition and relapse risk in pediatric MS: A pilot study. <i>Journal of the Neurological Sciences</i> , 2016 , 363, 153-7	3.2	110
431	Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. <i>Neurology</i> , 2001 , 56, 1324-30	6.5	109
430	Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. <i>Brain</i> , 2009 , 132, 3392-400	11.2	105
429	Common viruses associated with lower pediatric multiple sclerosis risk. <i>Neurology</i> , 2011 , 76, 1989-95	6.5	104
428	Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. <i>Journal of Child Neurology</i> , 2013 , 28, 102-7	2.5	103
427	Genomic effects of IFN-beta in multiple sclerosis patients. <i>Journal of Immunology</i> , 2003 , 171, 2694-702	5.3	103
426	Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. <i>Neurology</i> , 2011 , 76, 1500-7	6.5	102
425	Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. <i>Neurology</i> , 2009 , 73, 504-10	6.5	100
424	Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. <i>NeuroImage</i> , 2007 , 36, 1294-300	7.9	100
423	Epidemiology and treatment of multiple sclerosis in elderly populations. <i>Nature Reviews Neurology</i> , 2019 , 15, 329-342	15	99
422	Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. <i>Neurology</i> , 2017 , 88, 1623-1629	6.5	97
421	Upper and lower extremity motor function and cognitive impairment in multiple sclerosis. <i>Journal of the International Neuropsychological Society</i> , 2011 , 17, 643-53	3.1	97
420	Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. <i>Expert Review of Neurotherapeutics</i> , 2016 , 16, 777-93	4.3	94

419	MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2005 , 234, 17-24	3.2	92
418	Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 293-8	5	92
417	Clinical features of children and adolescents with multiple sclerosis. <i>Neurology</i> , 2007 , 68, S37-45	6.5	91
416	Extended interval dosing of natalizumab in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 885-9	5.5	90
415	In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. <i>Journal of Neuroimmunology</i> , 2001 , 116, 213-9	3.5	89
414	Lipid profiles are associated with lesion formation over 24 months in interferon- β treated patients following the first demyelinating event. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 1186-91	5.5	87
413	Risk of bone loss in men with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 170-5	5	87
412	Ultrasensitive quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry. <i>Analytical Chemistry</i> , 2010 , 82, 2488-97	7.8	86
411	Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. <i>Archives of Neurology</i> , 2011 , 68, 437-44		86
410	Aging and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 717-25	5	86
409	A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-relapsing multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). <i>Multiple Sclerosis Journal</i> , 1995 , 1, 118-35	5	85
408	Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. <i>Archives of Neurology</i> , 2005 , 62, 1371-6		83
407	Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 722-30	5	81
406	Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. <i>Journal of Neuroimmunology</i> , 1999 , 93, 8-14	3.5	81
405	Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. <i>Human Molecular Genetics</i> , 2007 , 16, 2659-68	5.6	79
404	Interpreting patient/informant discrepancies of reported cognitive symptoms in MS. <i>Journal of the International Neuropsychological Society</i> , 2005 , 11, 574-83	3.1	78
403	Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 181-7	5.5	77
402	Quercetin and interferon-beta modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2008 , 205, 142-7	3.5	76

401	Thalamic Involvement in Multiple Sclerosis: A Diffusion-Weighted Magnetic Resonance Imaging Study. <i>Journal of Neuroimaging</i> , 2003 , 13, 307-314	2.8	76
400	Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. <i>Neurology</i> , 2016 , 86, 245-52	6.5	75
399	Use of MR venography for characterization of the extracranial venous system in patients with multiple sclerosis and healthy control subjects. <i>Radiology</i> , 2011 , 258, 562-70	20.5	74
398	The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to imaging. <i>Neural Regeneration Research</i> , 2019 , 14, 373-386	4.5	74
397	Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 998-1005	5	72
396	Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. <i>Neurology</i> , 2011 , 77, 355-63	6.5	72
395	Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1478-84	5	71
394	Characterizing cognitive function during relapse in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1745-52	5	69
393	Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 189-95	5.5	69
392	Regional lobar atrophy predicts memory impairment in multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2005 , 26, 1824-31	4.4	69
391	Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1327-36	5	68
390	Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1336-1345	5	68
389	A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 573-82	5	67
388	The severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis is related to altered cerebrospinal fluid dynamics. <i>Functional Neurology</i> , 2009 , 24, 133-8	2.2	67
387	Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 588-96	5	66
386	Validity of the Wisconsin Card Sorting and Delis-Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2007 , 29, 215-23	2.1	66
385	Venous angioplasty in patients with multiple sclerosis: results of a pilot study. <i>European Journal of Vascular and Endovascular Surgery</i> , 2012 , 43, 116-22	2.3	64
384	Use of neck magnetic resonance venography, Doppler sonography and selective venography for diagnosis of chronic cerebrospinal venous insufficiency: a pilot study in multiple sclerosis patients and healthy controls. <i>International Angiology</i> , 2010 , 29, 127-39	2.2	64

383	Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. <i>Lancet Neurology, The</i> , 2008 , 7, 173-83	24.1	62
382	Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2003 , 209, 93-9	3.2	62
381	Hypoperfusion of brain parenchyma is associated with the severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a cross-sectional preliminary report. <i>BMC Medicine</i> , 2011 , 9, 22	11.4	61
380	Value of MR venography for detection of internal jugular vein anomalies in multiple sclerosis: a pilot longitudinal study. <i>American Journal of Neuroradiology</i> , 2011 , 32, 938-46	4.4	60
379	Pattern reversal visual evoked potentials as a measure of visual pathway pathology in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 529-34	5	60
378	Impact of diagnosis and early treatment on the course of multiple sclerosis. <i>American Journal of Managed Care</i> , 2013 , 19, s321-31	2.1	60
377	Interferon β for Multiple Sclerosis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018 , 8,	5.4	57
376	Comparison of three different methods for measurement of cervical cord atrophy in multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2008 , 29, 319-25	4.4	57
375	MRI features of pediatric multiple sclerosis. <i>Neurology</i> , 2007 , 68, S46-53	6.5	57
374	Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1502-10	5	56
373	Iron deposition in multiple sclerosis lesions measured by susceptibility-weighted imaging filtered phase: a case control study. <i>Journal of Magnetic Resonance Imaging</i> , 2012 , 36, 73-83	5.6	55
372	Cerebral Microbleeds in Multiple Sclerosis Evaluated on Susceptibility-weighted Images and Quantitative Susceptibility Maps: A Case-Control Study. <i>Radiology</i> , 2016 , 281, 884-895	20.5	54
371	Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. <i>Journal of Neurology</i> , 2012 , 259, 898-905	5.5	54
370	Characteristics of Children and Adolescents With Multiple Sclerosis. <i>Pediatrics</i> , 2016 , 138,	7.4	52
369	Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: a pilot case-control study. <i>International Angiology</i> , 2010 , 29, 158-75	2.2	52
368	Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. <i>Archives of Neurology</i> , 2010 , 67, 1329-35		51
367	Iron deposition on SWI-filtered phase in the subcortical deep gray matter of patients with clinically isolated syndrome may precede structure-specific atrophy. <i>American Journal of Neuroradiology</i> , 2012 , 33, 1596-601	4.4	51
366	Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2010 , 292, 28-35	3.2	50

365	Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study. <i>PLoS ONE</i> , 2013 , 8, e53996	3.7	50
364	Fatigue and depression in children with demyelinating disorders. <i>Journal of Child Neurology</i> , 2013 , 28, 713-8	2.5	49
363	Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009 , 80, 620-5	5.5	49
362	Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2007 , 188, 167-74	3.5	49
361	Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Database. <i>International Journal of MS Care</i> , 2018 , 20, 9-14	2.3	49
360	Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis. <i>Radiology</i> , 2018 , 289, 487-496	20.5	48
359	Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study. <i>European Journal of Neurology</i> , 2019 , 26, 87-e8	6	48
358	Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 1-5	5	48
357	Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 626-34	5	48
356	Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2010 , 223, 92-9	3.5	47
355	Distinct effects of obesity and puberty on risk and age at onset of pediatric MS. <i>Annals of Clinical and Translational Neurology</i> , 2016 , 3, 897-907	5.3	47
354	Gender-related differences in MS: a study of conventional and nonconventional MRI measures. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 345-54	5	46
353	Multiple sclerosis gender issues: clinical practices of women neurologists. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 582-8	5	46
352	Retinal nerve fiber thickness in inflammatory demyelinating diseases of childhood onset. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 802-10	5	45
351	Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality. <i>NeuroImage</i> , 2018 , 167, 438-452	7.9	43
350	Comparison of the immunomodulatory effects of the plant sterol beta-sitosterol to simvastatin in peripheral blood cells from multiple sclerosis patients. <i>International Immunopharmacology</i> , 2009 , 9, 153-7	5.8	43
349	What is new in the treatment of multiple sclerosis?. <i>Drugs</i> , 2000 , 59, 401-10	12.1	43
348	Dietary salt intake and time to relapse in paediatric multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1350-1353	5.5	43

347	A case-control study of dietary salt intake in pediatric-onset multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 6, 87-92	4	43
346	Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. <i>Neurology</i> , 2017 , 89, 1584-1593	6.5	42
345	Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency. <i>BMC Neurology</i> , 2011 , 11, 128	3.1	42
344	Increased tissue damage and lesion volumes in African Americans with multiple sclerosis. <i>Neurology</i> , 2010 , 74, 538-44	6.5	42
343	Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. <i>NeuroImage</i> , 2007 , 36, 746-54	7.9	42
342	Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers. <i>Journal of the Neurological Sciences</i> , 2013 , 330, 71-7	3.2	40
341	Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. <i>Neurology</i> , 2012 , 78, 1171-8	6.5	40
340	Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2007 , 187, 159-65	3.5	40
339	Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. <i>Journal of Neuroimmunology</i> , 2006 , 176, 125-33	3.5	40
338	Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 858-65	5	39
337	Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. <i>Annals of Clinical and Translational Neurology</i> , 2019 , 6, 1757-1770	5.3	39
336	Chronic cerebrospinal venous insufficiency in multiple sclerosis: diagnostic, pathogenetic, clinical and treatment perspectives. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 1277-94	4.3	39
335	Intra- and extraluminal structural and functional venous anomalies in multiple sclerosis, as evidenced by 2 noninvasive imaging techniques. <i>American Journal of Neuroradiology</i> , 2012 , 33, 16-23	4.4	39
334	HLA-DP: a class II restriction molecule involved in epitope spreading during the development of multiple sclerosis. <i>Human Immunology</i> , 1998 , 59, 15-24	2.3	39
333	Cortical atrophy and personality in multiple sclerosis. <i>Neuropsychology</i> , 2008 , 22, 432-41	3.8	39
332	Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation. <i>American Journal of Neuroradiology</i> , 2004 , 25, 985-96	4.4	39
331	Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 759-63	5	38
330	Prevalence of radiologically isolated syndrome and white matter signal abnormalities in healthy relatives of patients with multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2014 , 35, 106-12	4.4	37

329	Cine cerebrospinal fluid imaging in multiple sclerosis. <i>Journal of Magnetic Resonance Imaging</i> , 2012 , 36, 825-34	5.6	37
328	Phytosterols ameliorate clinical manifestations and inflammation in experimental autoimmune encephalomyelitis. <i>Inflammation Research</i> , 2011 , 60, 457-65	7.2	36
327	TREATMENT OF FULMINANT MULTIPLE SCLEROSIS WITH INTRAVENOUS CYCLOPHOSPHAMIDE. <i>Neurologist</i> , 1997 , 3, 178-185	1.6	36
326	Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2018 , 28, 490-495	2.8	35
325	Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2007 , 182, 236-9	3.5	34
324	Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients. <i>Journal of Lipid Research</i> , 2015 , 56, 2010-8	6.3	33
323	MRI in the evaluation of pediatric multiple sclerosis. <i>Neurology</i> , 2016 , 87, S88-96	6.5	33
322	Influence of cognitive function on speech and articulation rate in multiple sclerosis. <i>Journal of the International Neuropsychological Society</i> , 2013 , 19, 173-80	3.1	33
321	Mechanisms of interferon-beta effects on bone homeostasis. <i>Biochemical Pharmacology</i> , 2009 , 77, 1757-62		33
320	Interferon-beta treatment for relapsing multiple sclerosis. <i>Expert Opinion on Biological Therapy</i> , 2008 , 8, 1435-47	5.4	33
319	Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 1061-7	5	33
318	Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1670-1681		33
317	Subcortical deep gray matter pathology in patients with multiple sclerosis is associated with white matter lesion burden and atrophy but not with cortical atrophy: a diffusion tensor MRI study. <i>American Journal of Neuroradiology</i> , 2014 , 35, 912-9	4.4	32
316	Differential effects of aging on motor and cognitive functioning in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1385-1393	5	32
315	Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2008 , 205, 113-25	3.5	32
314	Construct validity and frequency of euphoria sclerotica in multiple sclerosis. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2004 , 16, 350-6	2.7	32
313	Thalamic Involvement in Multiple Sclerosis: A Diffusion-Weighted Magnetic Resonance Imaging Study 2003 , 13, 307		32
312	Benchmarks of meaningful impairment on the MSFC and BICAMS. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1874-1882	5	32

311	Negative work events and accommodations in employed multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 116-9	5	31
310	Risk factors for chronic cerebrospinal venous insufficiency (CCSVI) in a large cohort of volunteers. <i>PLoS ONE</i> , 2011 , 6, e28062	3.7	31
309	Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings. <i>Neurodegenerative Disease Management</i> , 2019 , 9, 149-172	2.8	30
308	Interdependence of oxysterols with cholesterol profiles in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 792-801	5	30
307	Speech and pause characteristics in multiple sclerosis: a preliminary study of speakers with high and low neuropsychological test performance. <i>Clinical Linguistics and Phonetics</i> , 2013 , 27, 134-51	1.4	30
306	Natalizumab in pediatric multiple sclerosis patients. <i>Therapeutic Advances in Neurological Disorders</i> , 2010 , 3, 293-9	6.6	30
305	Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2009 , 209, 123-30	3.5	30
304	Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 541-50	5	30
303	Changes of cine cerebrospinal fluid dynamics in patients with multiple sclerosis treated with percutaneous transluminal angioplasty: a case-control study. <i>Journal of Vascular and Interventional Radiology</i> , 2013 , 24, 829-38	2.4	29
302	Prospective randomized trial of venous angioplasty in MS (PREMiSe). <i>Neurology</i> , 2014 , 83, 441-9	6.5	29
301	Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ1a in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1125-34	5	29
300	Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study. <i>Journal of Neurology</i> , 2013 , 260, 489-97	5.5	29
299	Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. <i>Neurology</i> , 2018 , 91, e1778-e1787	6.5	29
298	Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 1075-81	5.5	28
297	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , 2020 , 19, 988-997	24.1	28
296	Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 859-64	5.5	27
295	Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions. <i>CNS Drugs</i> , 2014 , 28, 731-42	6.7	27
294	Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 891-5	5	27

293	Cerebellar mutism in pediatric acute disseminated encephalomyelitis. <i>Pediatric Neurology</i> , 2010 , 42, 259-266	27
292	Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis. <i>Annals of Neurology</i> , 2020 , 88, 42-55	9.4 26
291	Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2018 , 39, 642-647	4.4 26
290	Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 770-81	5 26
289	The NEO-FFI in Multiple Sclerosis: internal consistency, factorial validity, and correspondence between self and informant reports. <i>Assessment</i> , 2011 , 18, 39-49	3.7 26
288	Genetic risk factors for pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1825-1834	5 25
287	Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. <i>The Cochrane Library</i> , 2016 , 11, CD009333	5.2 25
286	Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2011 , 311, 86-91	3.2 25
285	Regression-based pediatric norms for the brief visuospatial memory test: revised and the symbol digit modalities test. <i>Clinical Neuropsychologist</i> , 2011 , 25, 402-12	4.4 25
284	Two decades of glatiramer acetate: From initial discovery to the current development of generics. <i>Journal of the Neurological Sciences</i> , 2017 , 376, 255-259	3.2 24
283	Cognitive Profiles of Aging in Multiple Sclerosis. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 105	5.3 24
282	Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e190	9.1 24
281	Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. <i>Journal of Neuroimmunology</i> , 2016 , 292, 68-78	3.5 24
280	The neurological disease ontology. <i>Journal of Biomedical Semantics</i> , 2013 , 4, 42	2.2 24
279	Patterns of dietary and herbal supplement use by multiple sclerosis patients. <i>Journal of Neurology</i> , 2012 , 259, 637-44	5.5 24
278	A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2010 , 3, 15-28	6.6 24
277	Visual-cognitive processing deficits in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 449-56	5 24
276	Serum lipid profile changes predict neurodegeneration in interferon-βa-treated multiple sclerosis patients. <i>Journal of Lipid Research</i> , 2017 , 58, 403-411	6.3 23

275	Assessing No Evidence of Disease Activity Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study. <i>CNS Drugs</i> , 2018 , 32, 75-84	6.7	23
274	Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. <i>BMC Neurology</i> , 2013 , 13, 80	3.1	23
273	Comparison of intravascular ultrasound with conventional venography for detection of extracranial venous abnormalities indicative of chronic cerebrospinal venous insufficiency. <i>Journal of Vascular and Interventional Radiology</i> , 2013 , 24, 1487-98.e1	2.4	23
272	Sensitivity and specificity for screening of chronic cerebrospinal venous insufficiency using a multimodal non-invasive imaging approach in patients with multiple sclerosis. <i>Functional Neurology</i> , 2011 , 26, 205-14	2.2	23
271	Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?. <i>Expert Review of Neurotherapeutics</i> , 2016 , 16, 765-75	4.3	23
270	Maternal and Perinatal Exposures Are Associated With Risk for Pediatric-Onset Multiple Sclerosis. <i>Pediatrics</i> , 2017 , 139,	7.4	22
269	Identifying employed multiple sclerosis patients at-risk for job loss: When do negative work events pose a threat?. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 409-413	4	22
268	Disclosure of disease status among employed multiple sclerosis patients: association with negative work events and accommodations. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 225-34	5	22
267	Separate and Combined Influence of Cognitive Impairment and Dysarthria on Functional Communication in Multiple Sclerosis. <i>American Journal of Speech-Language Pathology</i> , 2018 , 27, 1051-1065	2.1	22
266	Aqueductal cerebrospinal fluid pulsatility in healthy individuals is affected by impaired cerebral venous outflow. <i>Journal of Magnetic Resonance Imaging</i> , 2014 , 40, 1215-22	5.6	22
265	Simultaneous determination of oxysterols, cholesterol and 25-hydroxy-vitamin D3 in human plasma by LC-UV-MS. <i>PLoS ONE</i> , 2015 , 10, e0123771	3.7	22
264	Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 567-76	5	22
263	Cognitive and White Matter Tract Differences in MS and Diffuse Neuropsychiatric Systemic Lupus Erythematosus. <i>American Journal of Neuroradiology</i> , 2015 , 36, 1874-83	4.4	21
262	Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1243-1254	5	21
261	Treatment of multiple sclerosis in children and adolescents. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 505-20	4	21
260	Fingolimod for the treatment of relapsing multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 165-83	4.3	21
259	Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. <i>Current Medical Research and Opinion</i> , 2009 , 25, 2459-70	2.5	21
258	Lower Arterial Cross-Sectional Area of Carotid and Vertebral Arteries and Higher Frequency of Secondary Neck Vessels Are Associated with Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2018 , 39, 123-130	4.4	21

257	Urban air quality and associations with pediatric multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1146-1153	5.3	21
256	Thalamic involvement in multiple sclerosis: a diffusion-weighted magnetic resonance imaging study 2003 , 13, 307-14		21
255	CSF dynamics and brain volume in multiple sclerosis are associated with extracranial venous flow anomalies: a pilot study. <i>International Angiology</i> , 2010 , 29, 140-8	2.2	21
254	Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis. <i>Human Brain Mapping</i> , 2019 , 40, 5231-5241	5.9	20
253	Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. <i>PLoS Genetics</i> , 2019 , 15, e1007808	6	20
252	Changes of deep gray matter magnetic susceptibility over 21 years in multiple sclerosis and healthy control brain. <i>NeuroImage: Clinical</i> , 2018 , 18, 1007-1016	5.3	20
251	Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis. <i>CNS Drugs</i> , 2016 , 30, 209-25	6.7	20
250	Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage. <i>Journal of the Neurological Sciences</i> , 2018 , 393, 128-134	3.2	20
249	Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2012 , 243, 61-8	3.5	20
248	Ocrelizumab: a B-cell depleting therapy for multiple sclerosis. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 1163-1172	5.4	20
247	Influence of personality on the relationship between gray matter volume and neuropsychiatric symptoms in multiple sclerosis. <i>Psychosomatic Medicine</i> , 2013 , 75, 253-61	3.7	20
246	MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. <i>Journal of Neurology</i> , 2010 , 257, 63-71	5.5	20
245	Dynamics of immune cell trafficking in interferon-beta treated multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2003 , 139, 84-92	3.5	20
244	Cognition and physical disability in predicting health-related quality of life in multiple sclerosis. <i>International Journal of MS Care</i> , 2011 , 13, 57-63	2.3	20
243	Improved relapse recovery in paediatric compared to adult multiple sclerosis. <i>Brain</i> , 2020 , 143, 2733-2741	11.2	20
242	Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study. <i>Journal of Neurology</i> , 2019 , 266, 866-875	5.5	20
241	Oxysterols and apolipoproteins in multiple sclerosis: a 5 year follow-up study. <i>Journal of Lipid Research</i> , 2019 , 60, 1190-1198	6.3	19
240	Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS. <i>American Journal of Neuroradiology</i> , 2018 , 38, 200-205	4.4	19

239	Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS. <i>Neurology</i> , 2019 , 93, e611-e623	6.5	19
238	Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis. <i>Advances in Therapy</i> , 2011 , 28, 270-8	4.1	19
237	Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 734-42	5	19
236	Regression-based norms improve the sensitivity of the National MS Society Consensus Neuropsychological Battery for Pediatric Multiple Sclerosis (NBPMS). <i>Clinical Neuropsychologist</i> , 2012 , 26, 985-1002	4.4	19
235	Recovery of cognitive function after relapse in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 71-78	5	19
234	Hemostasis biomarkers in multiple sclerosis. <i>European Journal of Neurology</i> , 2018 , 25, 1169-1176	6	19
233	Detection of cytochrome P450 and other drug-metabolizing enzyme mRNAs in peripheral blood mononuclear cells using DNA arrays. <i>Drug Metabolism and Disposition</i> , 2000 , 28, 987-93	4	19
232	Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. <i>Radiology</i> , 2019 , 293, 424-433	20.5	18
231	Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective. <i>Vaccines</i> , 2020 , 8,	5.3	18
230	An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis. <i>CNS Drugs</i> , 2018 , 32, 161-178	6.7	18
229	Protective environmental factors for neuromyelitis optica. <i>Neurology</i> , 2014 , 83, 1923-9	6.5	18
228	Gray matter SWI-filtered phase and atrophy are linked to disability in MS. <i>Frontiers in Bioscience - Elite</i> , 2013 , 5, 525-32	1.6	18
227	The rs2030324 SNP of brain-derived neurotrophic factor (BDNF) is associated with visual cognitive processing in multiple sclerosis. <i>Pathophysiology</i> , 2011 , 18, 43-52	1.8	18
226	Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: A voxel-based morphometry study. <i>Pathophysiology</i> , 2011 , 18, 53-60	1.8	18
225	Arterial, venous and other vascular risk factors in multiple sclerosis. <i>Neurological Research</i> , 2012 , 34, 754-60	2.7	18
224	Combination therapy for multiple sclerosis: the treatment strategy of the future?. <i>CNS Drugs</i> , 2004 , 18, 777-92	6.7	18
223	Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 201-209	5	18
222	Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals. <i>NeuroImage: Clinical</i> , 2018 , 17, 530-540	5.3	18

221	Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine. <i>American Journal of Neuroradiology</i> , 2018 , 39, 2237-2242	4.4	18
220	Vascular aspects of multiple sclerosis: emphasis on perfusion and cardiovascular comorbidities. <i>Expert Review of Neurotherapeutics</i> , 2019 , 19, 445-458	4.3	17
219	Dietary inflammatory index and risk of multiple sclerosis: Findings from a large population-based incident case-control study. <i>Clinical Nutrition</i> , 2020 , 39, 3402-3407	5.9	17
218	Dietary factors and pediatric multiple sclerosis: A case-control study. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1067-1076	5	17
217	Synergistic Effects of Reserve and Adaptive Personality in Multiple Sclerosis. <i>Journal of the International Neuropsychological Society</i> , 2016 , 22, 920-927	3.1	17
216	Long-Term Neurocognitive, Psychosocial, and Magnetic Resonance Imaging Outcomes in Pediatric-Onset Acute Disseminated Encephalomyelitis. <i>Pediatric Neurology</i> , 2016 , 57, 64-73	2.9	17
215	Examining the contributions of environmental quality to pediatric multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 18, 164-169	4	17
214	Active cognitive reserve influences the regional atrophy to cognition link in multiple sclerosis. <i>Journal of the International Neuropsychological Society</i> , 2013 , 19, 1128-33	3.1	17
213	Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2000 , 6, 373-377	5	17
212	Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 99-108	5	17
211	Heterogeneity in association of remote herpesvirus infections and pediatric MS. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1222-1228	5.3	17
210	An update on new and emerging therapies for relapsing-remitting multiple sclerosis. <i>American Journal of Managed Care</i> , 2013 , 19, s343-54	2.1	17
209	Aging and Brain Atrophy in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2019 , 29, 527-535	2.8	16
208	The US Network of Pediatric Multiple Sclerosis Centers: Development, Progress, and Next Steps. <i>Journal of Child Neurology</i> , 2015 , 30, 1381-7	2.5	16
207	Blood circulating microparticle species in relapsing-remitting and secondary progressive multiple sclerosis. A case-control, cross sectional study with conventional MRI and advanced iron content imaging outcomes. <i>Journal of the Neurological Sciences</i> , 2015 , 355, 84-9	3.2	16
206	Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. <i>Journal of Neurology</i> , 2015 , 262, 326-36	5.5	16
205	Longitudinal personality change associated with cognitive decline in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 1352458517753720	5	16
204	Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2016 , 37, 1010-6	4.4	16

203	White matter tract network disruption explains reduced conscientiousness in multiple sclerosis. <i>Human Brain Mapping</i> , 2018 , 39, 3682-3690	5.9	16
202	Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. <i>Cochrane Database of Systematic Reviews</i> , 2014 , CD009333		16
201	Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome. <i>Journal of the Neurological Sciences</i> , 2014 , 338, 128-34	3.2	16
200	Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: results from the multi-center set study. <i>Journal of Neuroimmunology</i> , 2014 , 273, 58-64	3.5	16
199	Vitamin D and multiple sclerosis. <i>Neurologist</i> , 2012 , 18, 179-83	1.6	16
198	Improved cognitive performance and event-related potential changes following working memory training in patients with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018 , 4, 2055217317747626	2	15
197	Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk. <i>Journal of the Neurological Sciences</i> , 2016 , 370, 13-17	3.2	15
196	Retinal nerve fiber layer thickness and thalamus pathology in multiple sclerosis patients. <i>European Journal of Neurology</i> , 2014 , 21, 1137-e61	6	15
195	Cognitive impairment is associated with reduced bone mass in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1459-65	5	15
194	Personality traits in women with multiple sclerosis: discrepancy in patient/partner report and disease course. <i>Journal of Psychosomatic Research</i> , 2009 , 66, 147-54	4.1	15
193	Interferon inhibitory activity in patients with multiple sclerosis. <i>Archives of Neurology</i> , 2006 , 63, 1579-84		15
192	Complementary and Alternative Medicine Usage by Multiple Sclerosis Patients: Results from a Prospective Clinical Study. <i>Journal of Alternative and Complementary Medicine</i> , 2018 , 24, 596-602	2.4	14
191	Plasma pentosidine: a potential biomarker in the management of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 157-63	5	14
190	Functional imaging during covert auditory attention in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2004 , 218, 9-15	3.2	14
189	Chronic cerebrospinal vascular insufficiency is not associated with HLA DRB1*1501 status in multiple sclerosis patients. <i>PLoS ONE</i> , 2011 , 6, e16802	3.7	14
188	Impact of Nutritional Intake on Function in People with Mild-to-Moderate Multiple Sclerosis. <i>International Journal of MS Care</i> , 2019 , 21, 1-9	2.3	14
187	Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years. <i>European Journal of Neurology</i> , 2016 , 23, 1101-9	6	14
186	Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 322-332	5	14

185	An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice-The MS-MRIUS Study. <i>Journal of Neuroimaging</i> , 2017 , 27, 339-347	2.8	13
184	Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study. <i>American Journal of Neuroradiology</i> , 2019 , 40, 620-625	4.4	13
183	Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 937-43	5.5	13
182	Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014 , 143, 424-33 ¹	5.1	13
181	Cholesterol affects retinal nerve fiber layer thickness in patients with multiple sclerosis with optic neuritis. <i>European Journal of Neurology</i> , 2013 , 20, 1264-71	6	13
180	No association between conventional brain MR imaging and chronic cerebrospinal venous insufficiency in multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2012 , 33, 1913-7	4.4	13
179	Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study. <i>PLoS ONE</i> , 2014 , 9, e91098	3.7	13
178	Teriflunomide [®] effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 36, 101388	4	12
177	Lipid profile is associated with decreased fatigue in individuals with progressive multiple sclerosis following a diet-based intervention: Results from a pilot study. <i>PLoS ONE</i> , 2019 , 14, e0218075	3.7	12
176	Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 34, 103-111	4	12
175	Preliminary investigation of cognitive function in aged multiple sclerosis patients: Challenges in detecting comorbid Alzheimer [®] disease. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 22, 52-56	4	12
174	Five-Year Longitudinal Study of Neck Vessel Cross-Sectional Area in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2018 , 39, 1703-1709	4.4	12
173	Thalamic white matter in multiple sclerosis: A combined diffusion-tensor imaging and quantitative susceptibility mapping study. <i>Human Brain Mapping</i> , 2018 , 39, 4007-4017	5.9	12
172	Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: results of the PREMise pilot study. <i>BMC Neurology</i> , 2013 , 13, 151	3.1	12
171	Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 1016-20	5.5	12
170	Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis. <i>BMC Neurology</i> , 2012 , 12, 26	3.1	12
169	Prescribing recommendations for interferon-Beta in multiple sclerosis. <i>CNS Drugs</i> , 1997 , 8, 102-12	6.7	12
168	Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	12

167	Dalfampridine benefits ambulation but not cognition in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 91-98	5	12
166	Vitamin D genes influence MS relapses in children. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 894-901	5	12
165	Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow-up. <i>European Journal of Neurology</i> , 2020 , 27, 188-e4	6	12
164	Increased contrast enhancing lesion activity in relapsing-remitting multiple sclerosis migraine patients. <i>NeuroImage: Clinical</i> , 2015 , 9, 110-6	5.3	11
163	Use of natalizumab in multiple sclerosis: current perspectives. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1151-62	5.4	11
162	Immunologic and MRI markers of the therapeutic effect of IFN- β 1a in relapsing-remitting MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e176	9.1	11
161	Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 115-26	5.4	11
160	An association between autoreactive antibodies and anti-interferon-beta antibodies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 895-9	5	11
159	Assessment of mesoscopic properties of deep gray matter iron through a model-based simultaneous analysis of magnetic susceptibility and R* - A pilot study in patients with multiple sclerosis and normal controls. <i>NeuroImage</i> , 2019 , 186, 308-320	7.9	11
158	Stress-full life events and multiple sclerosis: A population-based incident case-control study. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 26, 168-172	4	11
157	Impact of Focal White Matter Damage on Localized Subcortical Gray Matter Atrophy in Multiple Sclerosis: A 5-Year Study. <i>American Journal of Neuroradiology</i> , 2018 , 39, 1480-1486	4.4	11
156	Stable neuropsychiatric status in multiple sclerosis: a 3-year study. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 569-74	5	10
155	Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study. <i>Journal of Comparative Effectiveness Research</i> , 2019 , 8, 305-316	2.1	10
154	Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures. <i>Journal of the Neurological Sciences</i> , 2018 , 388, 175-181	3.2	10
153	Trait neuroticism, extraversion, and conscientiousness in multiple sclerosis: Link to cognitive impairment?. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 205-213	5	10
152	Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. <i>Journal of Neuroimmunology</i> , 2013 , 263, 121-7	3.5	10
151	The management of pediatric multiple sclerosis. <i>Journal of Child Neurology</i> , 2012 , 27, 1384-93	2.5	10
150	HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. <i>Journal of Neuroimmunology</i> , 2011 , 236, 76-80	3.5	10

149	Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study. <i>Neurological Research</i> , 2012 , 34, 761-9	2.7	10
148	Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). <i>CNS Drugs</i> , 2021 , 35, 743-767	6.7	10
147	Lower self-report fatigue in multiple sclerosis is associated with localized white matter tract disruption between amygdala, temporal pole, insula, and other connected structures. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 27, 298-304	4	10
146	Plasma levels of soluble NCAM in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2019 , 396, 36-43.	3.2	10
145	Long-standing multiple sclerosis neurodegeneration: volumetric magnetic resonance imaging comparison to Parkinson disease, mild cognitive impairment, Alzheimer disease, and elderly healthy controls. <i>Neurobiology of Aging</i> , 2020 , 90, 84-92	5.6	9
144	High-density lipoprotein cholesterol is associated with multiple sclerosis fatigue: A fatigue-metabolism nexus?. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 654-663.e1	4.9	9
143	Phase white matter signal abnormalities in patients with clinically isolated syndrome and other neurologic disorders. <i>American Journal of Neuroradiology</i> , 2014 , 35, 1916-23	4.4	9
142	Laquinimod therapy in multiple sclerosis: a comprehensive review. <i>Neurology and Therapy</i> , 2014 , 3, 29-39.	4.6	9
141	Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. <i>BMC Neurology</i> , 2015 , 15, 232	3.1	9
140	Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology</i> , 2014 , 83, 1484-6	6.5	9
139	Tract-based spatial statistics analysis of diffusion-tensor imaging data in pediatric- and adult-onset multiple sclerosis. <i>Human Brain Mapping</i> , 2014 , 35, 53-60	5.9	9
138	The nervous system's potential role in multiple sclerosis associated bone loss. <i>Journal of the Neurological Sciences</i> , 2012 , 319, 8-14	3.2	9
137	Heart disease, overweight, and cigarette smoking are associated with increased prevalence of extra-cranial venous abnormalities. <i>Neurological Research</i> , 2012 , 34, 819-27	2.7	9
136	Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 245-252	5	9
135	Decreasing brain iron in multiple sclerosis: The difference between concentration and content in iron MRI. <i>Human Brain Mapping</i> , 2021 , 42, 1463-1474	5.9	9
134	A new perspective on proxy report: Investigating implicit processes of understanding through patient-proxy congruence. <i>Quality of Life Research</i> , 2015 , 24, 2637-49	3.7	8
133	Functional Connectivity and Structural Disruption in the Default-Mode Network Predicts Cognitive Rehabilitation Outcomes in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2020 , 30, 523-530	2.8	8
132	Increased CCL18 plasma levels are associated with neurodegenerative MRI outcomes in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 25, 37-42	4	8

131	Infectious exposure, antibiotic use, and multiple sclerosis: A population-based incident case-control study. <i>Acta Neurologica Scandinavica</i> , 2018 , 138, 308-314	3.8	8
130	Fingolimod β Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS. <i>Journal of Neuroimaging</i> , 2018 , 28, 399-405	2.8	8
129	Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 830-6	5	8
128	Is There Extra Cost of Institutional Care for MS Patients?. <i>Multiple Sclerosis International</i> , 2013 , 2013, 713627	1.1	8
127	Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis. A case-control diffusion imaging study. <i>Pathophysiology</i> , 2011 , 18, 61-8	1.8	8
126	Multiple sclerosis in 2011: Advances in therapy, imaging and risk factors in MS. <i>Nature Reviews Neurology</i> , 2012 , 8, 66-8	15	8
125	Marijuana Use by Patients with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2019 , 21, 57-62	2.3	8
124	Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1938-1947	5	8
123	Apolipoproteins AI and E are associated with neuroaxonal injury to gray matter in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 45, 102389	4	8
122	Necessity of technicians for computerized neuropsychological assessment devices in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 109-113	5	8
121	Sex-Specific Differences in Life Span Brain Volumes in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2020 , 30, 342-350	2.8	7
120	The role of dietary antioxidant index and index of nutritional quality in MS onset: finding from an Iranian population-based incident case-control study. <i>Nutritional Neuroscience</i> , 2020 , 1-8	3.6	7
119	Effect of dimethyl fumarate on gray and white matter pathology in subjects with relapsing multiple sclerosis: a longitudinal study. <i>European Journal of Neurology</i> , 2018 , 25, 584-e36	6	7
118	MRI segmentation analysis in temporal lobe and idiopathic generalized epilepsy. <i>BMC Neurology</i> , 2014 , 14, 131	3.1	7
117	Role of venoplasty for treatment of multiple sclerosis: value of open-label studies and surrogate treatment outcomes. <i>Journal of Vascular and Interventional Radiology</i> , 2012 , 23, 1308-10	2.4	7
116	Funding CCSVI research is/was a waste of valuable time, money and intellectual energy: no. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 858-60	5	7
115	Disease progression in pediatric multiple sclerosis: disparities between physical and neurocognitive outcomes. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 433-40	4.3	7
114	Sensitivity and specificity of SWI venography for detection of cerebral venous alterations in multiple sclerosis. <i>Neurological Research</i> , 2012 , 34, 793-801	2.7	7

113	Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data.. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 57, 103433	4	7
112	Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2020 ,	17.2	7
111	Manifestations and impact of the COVID-19 pandemic in neuroinflammatory diseases. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 918-928	5.3	7
110	Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	6
109	Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC). <i>BMC Neurology</i> , 2016 , 16, 102	3.1	6
108	Reserve-building activities in multiple sclerosis patients and healthy controls: a descriptive study. <i>BMC Neurology</i> , 2015 , 15, 135	3.1	6
107	Limb ataxia originating from peri-central sulcus demyelinating lesion in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2012 , 320, 136-40	3.2	6
106	MRI characteristics of familial and sporadic multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1145-52	5	6
105	Gerstmann-Strüssler-Scheinker syndrome masquerading as multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2011 , 309, 55-7	3.2	6
104	Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis. <i>PLoS ONE</i> , 2015 , 10, e0129503	3.7	6
103	A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis. <i>Journal of Neurology</i> , 2020 , 267, 802-811	5.5	6
102	Plasma levels of protein C pathway proteins and brain magnetic resonance imaging volumes in multiple sclerosis. <i>European Journal of Neurology</i> , 2020 , 27, 235-243	6	6
101	MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2020 , 20, 821-834	4.3	6
100	The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study. <i>CNS Drugs</i> , 2018 , 32, 763-770	6.7	6
99	Gut microbiome is associated with multiple sclerosis activity in children. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 1867-1883	5.3	6
98	Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study. <i>Journal of the Neurological Sciences</i> , 2018 , 387, 152-156	3.2	5
97	Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 9, 54-5	4	5
96	A decline in cognitive function should lead to a change in disease-modifying therapy - Yes. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1681-1682	5	5

95	Disease modifying therapies use associated with comorbid autoimmune diseases in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 228-33	4	5
94	New MRI criteria in the diagnosis of multiple sclerosis. <i>Lancet Neurology, The</i> , 2007 , 6, 664-5	24.1	5
93	Newer versus older treatments for relapsing-remitting multiple sclerosis. <i>Drug Safety</i> , 1996 , 14, 121-30	5.1	5
92	Lipoprotein(a) Levels Are Associated with the Size of Extracranial Arteries in Multiple Sclerosis. <i>Journal of Vascular Research</i> , 2020 , 57, 16-23	1.9	5
91	Late onset multiple sclerosis is associated with more severe ventricle expansion. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102588	4	5
90	Long-term drug treatment in multiple sclerosis: safety success and concerns. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 1121-1142	4.1	5
89	Late-onset cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine in an immunocompromised patient. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 2291-2292	5	5
88	Are Plasma Levels of Vascular Adhesion Protein-1 Associated Both with Cerebral Microbleeds in Multiple Sclerosis and Intracerebral Haemorrhages in Stroke?. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 175-178	7	5
87	Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 27, 65-73	4	5
86	Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1433-1436	5	5
85	miRNA contributions to pediatric-onset multiple sclerosis inferred from GWAS. <i>Annals of Clinical and Translational Neurology</i> , 2019 , 6, 1053-1061	5.3	4
84	A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis. <i>Therapeutic Advances in Neurological</i>	6.6	4
83	Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis. <i>Current Neurovascular Research</i> , 2017 , 14, 266-273	1.8	4
82	No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study. <i>Current Medical Research and Opinion</i> , 2018 , 34, 1431-1440	2.5	4
81	Cognitive deficits in pediatric-onset multiple sclerosis: what does the future hold?. <i>Neurodegenerative Disease Management</i> , 2014 , 4, 137-46	2.8	4
80	Transitions between SNF and home-based care in patients with multiple sclerosis. <i>NeuroRehabilitation</i> , 2014 , 34, 531-40	2	4
79	A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. <i>Multiple Sclerosis Journal</i> , 2000 , 6, 267-273	5	4
78	Decrease in Secondary Neck Vessels in Multiple Sclerosis: A 5-year Longitudinal Magnetic Resonance Angiography Study. <i>Current Neurovascular Research</i> , 2019 , 16, 215-223	1.8	4

77	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 675-684.e2	4.9	4
76	Reserve-related activities and MRI metrics in multiple sclerosis patients and healthy controls: an observational study. <i>BMC Neurology</i> , 2016 , 16, 108	3.1	4
75	Diagnosis of depression in multiple sclerosis is predicted by frontal-parietal white matter tract disruption. <i>Journal of Neurology</i> , 2021 , 268, 169-177	5.5	4
74	Conscientiousness and deterioration in employment status in multiple sclerosis over 3 years. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1125-1135	5	4
73	Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 47, 102653	4	4
72	Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population. <i>Journal of the Neurological Sciences</i> , 2017 , 375, 371-375	3.2	3
71	Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena?. <i>Clinical Autonomic Research</i> , 2019 , 29, 329-338	4.3	3
70	Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2019 , 29, 615-623	2.8	3
69	No regional gray matter atrophy differences between pediatric- and adult-onset relapsing-remitting multiple sclerosis. <i>Journal of Neuroimaging</i> , 2014 , 24, 63-7	2.8	3
68	Is Multiple Sclerosis Associated With a Lower Intraocular Pressure?. <i>Journal of Neuro-Ophthalmology</i> , 2017 , 37, 265-267	2.6	3
67	Comment on "no evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset". <i>Annals of Neurology</i> , 2011 , 69, 1062-3; author reply 1063	9.4	3
66	Multiple sclerosis: predicting risk and delaying progression. <i>Lancet Neurology</i> , 2010 , 9, 7-9	24.1	3
65	Pediatric Multiple Sclerosis Severity Score in a large US cohort. <i>Neurology</i> , 2020 , 95, e1844-e1853	6.5	3
64	Cortical and Deep Gray Matter Perfusion Associations With Physical and Cognitive Performance in Multiple Sclerosis Patients. <i>Frontiers in Neurology</i> , 2020 , 11, 700	4.1	3
63	High density lipoprotein cholesterol and apolipoprotein A-I are associated with greater cerebral perfusion in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2020 , 418, 117120	3.2	3
62	Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives. <i>Patient Related Outcome Measures</i> , 2019 , 10, 373-384	2.9	3
61	Thalamic Nuclei Volumes and Their Relationships to Neuroperformance in Multiple Sclerosis: A Cross-Sectional Structural MRI Study. <i>Journal of Magnetic Resonance Imaging</i> , 2021 , 53, 731-739	5.6	3
60	Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1077-1087	5	3

59	Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both?. <i>Journal of Neurology</i> , 2021 , 268, 2578-2588	5.5	3
58	Several household chemical exposures are associated with pediatric-onset multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1513-1521	5.3	3
57	Tonsillectomy in multiple sclerosis patients: Retrospective, case-controlled, exploratory study. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 42, 102131	4	2
56	Global and regional brain atrophy is associated with low or retrograde facial vein flow in multiple sclerosis. <i>Veins and Lymphatics</i> , 2017 , 6,	1.3	2
55	Regarding CCSVI and MS: a never-ending story or a new chapter?. <i>European Journal of Vascular and Endovascular Surgery</i> , 2012 , 43, 129-30	2.3	2
54	Retinal nerve fiber thickness and MRI white matter abnormalities in healthy relatives of multiple sclerosis patients. <i>Clinical Neurology and Neurosurgery</i> , 2013 , 115 Suppl 1, S49-54	2	2
53	Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study. <i>BMC Neurology</i> , 2013 , 13, 173	3.1	2
52	Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age.. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 57, 103406	4	2
51	Results of an Ongoing, Open-Label, Safety-Extension Study of Interferon Beta-1a (Avonex) Treatment in Multiple Sclerosis. <i>International Journal of MS Care</i> , 1999 , 1, 3-11	2.3	2
50	Fatigue and Mood States in Nursing Home and Nonambulatory Home-Based Patients with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2017 , 19, 297-302	2.3	2
49	Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2020 , 41, 1577-1583	4.4	2
48	Staging and stratifying cognitive dysfunction in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 1352458521101139	4.5	2
47	Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis. <i>Journal of Child Neurology</i> , 2019 , 34, 148-152	2.5	2
46	Medical History and Multiple Sclerosis: A Population-Based Incident Case-Control Study. <i>Neuroepidemiology</i> , 2019 , 52, 55-62	5.4	2
45	Quantifying disease pathology and predicting disease progression in multiple sclerosis with only clinical routine T2-FLAIR MRI. <i>NeuroImage: Clinical</i> , 2021 , 31, 102705	5.3	2
44	Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211035740	5	2
43	Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	2
42	Clinical effects associated with five-year retinal nerve fiber layer thinning in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2021 , 427, 117552	3.2	2

41	Comparison of a 1.5T standard vs. 3T optimized protocols in multiple sclerosis patients. <i>Minerva Medica</i> , 2012 , 103, 97-102	2.2	2
40	Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.. <i>CNS Drugs</i> , 2021 , 36, 45	6.7	2
39	No association between variations in extracranial venous anatomy and clinical outcomes in multiple sclerosis patients over 5 years. <i>BMC Neurology</i> , 2019 , 19, 121	3.1	1
38	Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly. <i>Journal of Neuroimmunology</i> , 2015 , 281, 44-50	3.5	1
37	Comparison of standard 1.5 T vs. 3 T optimized protocols in patients treated with glatiramer acetate. A serial MRI pilot study. <i>International Journal of Molecular Sciences</i> , 2012 , 13, 5659-73	6.3	1
36	Unusual long-standing Gd-DTPA enhancement in a chronic progressive myelopathy. <i>Journal of Computer Assisted Tomography</i> , 1995 , 19, 649-51	2.2	1
35	Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy. <i>Fluids and Barriers of the CNS</i> , 2020 , 17, 9	7	1
34	Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211049397	5	1
33	Functional network dynamics and decreased conscientiousness in multiple sclerosis. <i>Journal of Neurology</i> , 2021 , 1	5.5	1
32	Differential Diagnosis of Cognitive Decline in Elderly Individuals With Multiple Sclerosis. <i>Cognitive and Behavioral Neurology</i> , 2020 , 33, 294-300	1.6	1
31	Multiple sclerosis in 2019: predicting progression. <i>Lancet Neurology, The</i> , 2020 , 19, 12-14	24.1	1
30	Relationships Among Circulating Levels of Hemostasis Inhibitors, Chemokines, Adhesion Molecules, and MRI Characteristics in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020 , 11, 553616	4.1	1
29	Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis. <i>Diagnostics</i> , 2020 , 10,	3.8	1
28	Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2021 , 268, 4796-4808	5.5	1
27	The cholesterol autoxidation products, 7-ketocholesterol and 7-hydroxycholesterol are associated with serum neurofilaments in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 50, 102864	4	1
26	Diffusion tensor imaging reveals greater microstructure damage in lesional tissue that shrinks into cerebrospinal fluid in multiple sclerosis. <i>Journal of Neuroimaging</i> , 2021 , 31, 995-1002	2.8	1
25	Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes. <i>NeuroImage: Clinical</i> , 2021 , 29, 102554	5.3	1
24	Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives. <i>Neurodegenerative Disease Management</i> , 2021 , 11, 329-340	2.8	1

23	Asymptomatic infection after BNT162b2 mRNA COVID-19 vaccination in multiple sclerosis patient. <i>Acta Neurologica Belgica</i> , 2021 , 1	1.5	1
22	Association Between Time Spent Outdoors and Risk of Multiple Sclerosis. <i>Neurology</i> , 2021 ,	6.5	1
21	COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections. <i>Vaccines</i> , 2022 , 10, 695	5.3	1
20	Gene-environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211069926	5	0
19	Patient-Reported Outcome Severity and Emotional Salience Network Disruption in Multiple Sclerosis.. <i>Brain Imaging and Behavior</i> , 2022 , 1	4.1	0
18	Impact of Cognitive Impairment and Dysarthria on Spoken Language in Multiple Sclerosis. <i>Journal of the International Neuropsychological Society</i> , 2021 , 27, 450-460	3.1	0
17	Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 58, 103482	4	0
16	Three-Day Dietary Manipulation in Multiple Sclerosis: Exercise and Fatigue Outcomes. <i>International Journal of MS Care</i> , 2021 , 23, 199-205	2.3	0
15	Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. <i>NeuroImage: Clinical</i> , 2021 , 32, 102802	5.3	0
14	Considering patient age when treating multiple sclerosis across the adult lifespan. <i>Expert Review of Neurotherapeutics</i> , 2021 , 21, 353-364	4.3	0
13	Benchmarks of meaningful improvement on neurocognitive tests in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211044672	5	0
12	Peripheral nervous system electrodiagnostic abnormalities in predominantly Hispanic Multiple Sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 56, 103254	4	0
11	Early infectious exposures are not associated with increased risk of pediatric-onset multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 22, 103-107	4	
10	Regarding CCSVI: is blinding the key?. <i>European Journal of Vascular and Endovascular Surgery</i> , 2012 , 43, 126	2.3	
9	Management of pediatric multiple sclerosis632-644		
8	Devic's disease: Diagnostic and therapeutic challenge. <i>Multiple Sclerosis Journal</i> , 1997 , 3, 408-408	5	
7	Treatment Considerations in Female MS Patients of Reproductive Age 2017 , 35-48		
6	Phytosterols (PS) as immunomodulators of Multiple Sclerosis (MS). <i>FASEB Journal</i> , 2010 , 24, 332.8	0.9	

- 5 Preliminary Support of a Behavioral Intervention for Trait Conscientiousness in Multiple Sclerosis.. *International Journal of MS Care*, **2022**, 24, 45-53 2.3
- 4 Multiple Sclerosis Subtypes **2016**, 55-65
- 3 Cerebral blood flow dependency on systemic arterial circulation in progressive multiple sclerosis.. *European Radiology*, **2022**, 1 8
- 2 A prospective study to validate the expanded timed get-up-and-go in a population with multiple sclerosis.. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2022**, 8, 20552173221099186
- 1 Plasma 24-hydroxycholesterol is associated with narrower common carotid artery and greater flow velocities in relapsing multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2022**, 103906 4